Patricia A. Martin, a director at AN2 Therapeutics, Inc., has acquired 389 shares of common stock as part of her compensation. This transaction, filed on October 13, 2026, is significant as it highlights the company's strategy to align director compensation with shareholder interests.
AN2 Therapeutics, Inc. is a company focused on pharmaceutical preparations, as indicated by its SIC classification of 2834. The firm is incorporated in Delaware and is based in Menlo Park, California. The company has been active in the market, with recent filings reflecting ongoing transactions related to its executives.
According to the recent SEC filing (accession number 0001193125-26-420641), the transaction occurred on October 12, 2026. The filing states, "Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately." Following this acquisition, Martin now holds a total of 19,252 shares of the company.
This acquisition may affect various stakeholders, including other directors, shareholders, and potential investors, as it reflects the company's commitment to aligning the interests of its directors with those of its shareholders. Such moves are increasingly common in the pharmaceutical industry as companies seek to enhance transparency and accountability in executive compensation.
The filing does not specify what happens next regarding Martin's role or any further transactions.